

Century Plyboards

India | Building Materials | Company Update



21 January 2026

Performance shines along with market share gains

Century Plyboards (CPBI IN) have been the most consistent company in the building materials space. It has been gaining market share in the plywood space, driven by identifying timely opportunity in the affordable segment through its *Sainik 710* and focusing on the premium segment through *Club Prime*. CPBI has achieved leadership in plywood with a 31% share in its focus INR 90bn market. The company plans to achieve an overall revenue CAGR of 17% during FY26-31, as it aims to generate a revenue of INR 120bn by FY31. It has a strong balance sheet to fund this growth, as the current D/E ratio stands at 0.3x (post an INR 20bn capex in the past three years). Sustained brand investments, loyalty program for intermediaries, and go to market initiatives would drive market share gains. We retain **Buy** with a lower TP of INR 935 on 40x September 2027E P/E.

Plywood brand investment, focus on Tier III & IV markets and capacity expansion: CPBI has reported low-teen growth in the past six quarters in the plywood segment. The company has focused on demand generation (loyalty program and advertising) vs mere capacity expansion by most building materials firms. We believe additional capacity at Hoshiarpur (60k cubic meter) in Punjab would add incremental revenue of INR 6bn. Increased focus on Tier III & IV markets and brand investment would enable CPBI to continue to gain market share and sustain teen growth in the plywood segment.

Improving MDF utilization and capacity expansion to drive growth: The company has doubled MDF capacity in the past three years, and overall utilization currently stands at 70%. It plans to further expand capacity by 25% at its new facility at Badvel in H1FY27 by a line addition. Stable raw material prices, lower imports (down 53% during January-October 2025) and improved utilization are likely- to drive MDF margin, which took a hit recently. As new capacity addition slows, industry margin may revert to 18-20% in the medium term. Management aims to improve overall capacity utilization to 90% in Q4FY27.

Particle board and laminates initiative to improve margin: CPBI is driving margin improvement through premiumization, exports, and cost-efficient capacity addition. In laminates, new leadership, lower marketing spend and a shift toward premium & exports have led to recovery, driven by rising white-label exports opportunities. Management targets 15-17% revenue growth and high single-digit EBITDA margin by FY26-end. In particle board, the commissioning of a continued-line unit has lowered cost via reduced resin use & waste and enabled entry into the 8x4 feet segment. While near-term margin remains under pressure due to oversupply, rising utilization to 55-60% in H2FY26 may support a gradual recovery toward ~15% steady-state EBITDA margin.

Retain Buy with a lower TP of INR 935: Stable input prices and margin improvements on the back of improved capacity utilization and focus on the premium segment would drive a 28% EBITDA CAGR during FY25-28E. We believe a 12% stock correction in the past one month provides a good entry point; we retain **Buy** with TP of INR 935 from INR 980 on 40x (unchanged) September 2027E P/E. We cut our EPS by ~10% for FY26E and ~4% each for FY27E & FY28E, due to higher depreciation and lower other income.

Key financials

YE March (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue (INR mn)	38,860	45,278	52,800	62,017	71,391
YoY (%)	6.6	16.5	16.6	17.5	15.1
EBITDA (INR mn)	5,319	4,866	6,512	8,637	10,358
EBITDA margin (%)	13.7	10.7	12.3	13.9	14.5
Adj PAT (INR mn)	3,375	1,987	2,812	4,540	5,876
YoY (%)	(10.3)	(41.1)	41.6	61.4	29.4
Fully DEPS (INR)	15.2	8.9	12.6	20.4	26.4
RoE (%)	16.4	8.7	11.2	16.0	17.8
RoCE (%)	16.8	10.1	11.6	15.5	17.5
P/E (x)	47.9	81.3	57.4	35.6	27.5
EV/EBITDA (x)	33.3	36.4	27.2	20.5	17.1

Note: Pricing as on 20 January 2026; Source: Company, Elara Securities Estimate

Rating: Buy

Target Price: INR 935

Upside: 29%

CMP: INR 726

As on 20 January 2026

Key data

Bloomberg	CPBI IN
Reuters Code	CNTP.NS
Shares outstanding (mn)	222
Market cap (INR bn/USD mn)	161 / 1,773
EV (INR bn/USD mn)	177 / 1,948
ADTV 3M (INR mn/USD mn)	83 / 1
52 week high/low	897 / 630
Free float (%)	27

Note: as on 20 January 2026; Source: Bloomberg

Price chart



Source: Bloomberg

	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Shareholding (%)				
Promoter	72.6	72.6	72.6	72.6
% Pledge	0.0	0.0	0.0	0.0
FII	4.5	4.6	4.4	4.3
DII	18.1	17.6	17.9	18.1
Others	4.8	5.2	5.0	5.0

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(2.4)	1.1	8.1
Century Plyboards	(3.9)	0.8	(8.4)
NSE Mid-cap	(2.6)	(0.9)	6.1
NSE Small-cap	(9.2)	(12.9)	(7.4)

Source: Bloomberg

Amit Purohit

Building Materials, FMCG, Paints
+91 22 6164 8594
amit.purohit@elaracapital.com

Associate
Shweta Upadhyay
shweta.upadhyay@elaracapital.com
Manas Rastogi
manas.rastogi@elaracapital.com




Financials (YE March)

Income Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Total Revenue	38,860	45,278	52,800	62,017	71,391
Gross Profit	18,506	20,940	25,475	30,543	35,516
EBITDA	5,319	4,866	6,512	8,637	10,358
EBIT	4,372	3,494	4,712	6,762	8,358
Interest expense	308	690	1,000	800	700
Other income	439	103	78	150	250
Exceptional/ Extra-ordinary items	(111)	(133)	-	-	-
PBT	4,392	2,773	3,790	6,112	7,908
Tax	1,138	912	970	1,565	2,024
Minority interest/Associates income	11	(8)	(8)	(8)	(8)
Reported PAT	3,264	1,853	2,812	4,540	5,876
Adjusted PAT	3,375	1,987	2,812	4,540	5,876
Balance Sheet (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Shareholders' Equity	22,117	23,651	26,154	30,194	35,423
Minority Interest	(51)	142	142	142	142
Trade Payables	2,856	3,572	3,807	4,472	5,148
Provisions & Other Current Liabilities	2,420	2,154	2,839	3,305	3,779
Total Borrowings	7,709	15,863	15,363	15,363	14,363
Other long term liabilities	511	300	258	301	344
Total liabilities & equity	35,561	45,682	48,563	53,777	59,200
Net Fixed Assets	21,788	27,710	28,611	29,236	30,236
Goodwill	13	13	13	13	13
Intangible assets	-	-	-	-	-
Business Investments / other NC assets	28	28	28	28	28
Cash, Bank Balances & treasury investments	642	491	3,323	5,016	6,494
Inventories	6,456	9,866	7,980	9,373	10,789
Sundry Debtors	4,168	5,000	5,483	6,441	7,414
Other Current Assets	2,466	2,574	3,125	3,671	4,226
Total Assets	35,561	45,682	48,563	53,777	59,200
Cash Flow Statement (INR mn)	FY24	FY25	FY26E	FY27E	FY28E
Cashflow from Operations	3,437	(533)	6,342	4,693	6,124
Capital expenditure	(9,698)	(7,294)	(2,701)	(2,500)	(3,000)
Acquisitions / divestitures	(27)	0	-	-	-
Other Business cashflow	-	-	-	-	-
Free Cash Flow	(6,287)	(7,827)	3,640	2,193	3,124
Cashflow from Financing	4,148	7,676	(809)	(499)	(1,646)
Net Change in Cash / treasury investments	(2,140)	(151)	2,831	1,693	1,478
Key assumptions & Ratios	FY24	FY25	FY26E	FY27E	FY28E
Dividend per share (INR)	1.0	1.0	1.4	2.2	2.9
Book value per share (INR)	99.4	106.3	117.5	135.7	159.2
RoCE (Pre-tax) (%)	16.8	10.1	11.6	15.5	17.5
ROIC (Pre-tax) (%)	18.0	10.2	12.2	17.1	19.9
ROE (%)	16.4	8.7	11.2	16.0	17.8
Asset Turnover (x)	2.2	1.8	1.9	2.1	2.4
Net Debt to Equity (x)	0.3	0.6	0.5	0.3	0.2
Net Debt to EBITDA (x)	1.3	3.2	1.8	1.2	0.8
Interest cover (x) (EBITDA/ int exp)	17.3	7.0	6.5	10.8	14.8
Total Working capital days (WC/rev)	82.0	105.9	98.7	106.3	109.4
Valuation	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	47.9	81.3	57.4	35.6	27.5
P/Sales (x)	4.2	3.6	3.1	2.6	2.3
EV/ EBITDA (x)	33.3	36.4	27.2	20.5	17.1
EV/ OCF (x)	52.3	(337.6)	28.4	38.3	29.4
FCF Yield	(3.5)	(4.4)	2.0	1.2	1.7
Price to BV (x)	7.3	6.8	6.2	5.4	4.6
Dividend yield (%)	0.1	0.1	0.2	0.3	0.4

Sales CAGR of 16.3% during FY25-28E


Note: Pricing as on 20 January 2026; Source: Company, Elara Securities Estimate

Exhibit 1: Diversified product portfolio ensures resilient performance




Note: FY25: Source: Company, Elara Securities Research

Exhibit 2: Revenue and Margin set to improve




Source: Company, Elara Securities Estimate

Exhibit 3: Plywood margin higher than industry margin




Source: Company, Elara Securities Research

Exhibit 4: MDF margin higher than industry margin




Source: Company, Elara Securities Research

Exhibit 5: CPBI plywood revenue with positive divergence from peers




Source: Company, Elara Securities Research

Exhibit 6: CPBI with stable volume growth in the plywood segment




Source: Company, Elara Securities Research

Exhibit 7: MDF segment contributing to EBITDA expansion



Source: Company, Elara Securities Estimate

Exhibit 8: Volume growth in MDF remains better than peers




Source: Company, Elara Securities Research

Exhibit 9: Quarterly segment-wise highlight

Category	Q2FY26 volume growth (%)	Comments
Plywood	15.6	<ul style="list-style-type: none"> Growth was supported by healthy volume growth and wider distribution reach There are no cost pressures in the segment; prices have softened in India, which helps reduce pressure from imports
Laminates	4.8	<ul style="list-style-type: none"> The segment sees increased demand in both domestic and exports markets, particularly for design-driven and premium SKU Improvement in realization is largely due to a sustainable premium mix
MDF	20.8	<ul style="list-style-type: none"> Slight moderation in margin was due to temporary cost pressure. Raw materials pressure included supply shortages of wood (timber) in North India due to significant rains and floods. However, South India market is stabilizing The planned line extension at the South India plant to increase capacity by ~25% in its new facility is expected to occur in H1FY27, delayed from H2 of this year
Particle Board	(4.8)	<ul style="list-style-type: none"> Management is confident that the quality of the particle board will enable a robust ramp-up in sales The company is confident of achieving 40% sales growth during FY25-26, especially after factoring in capitalized trial sales run-rate

Source: Company, Elara Securities Research

Exhibit 10: Demand-supply gap to narrow as utilization improves



Note: Data does not include Action Tessa and unorganised firms data; Source: Company, Elara Securities Estimate

Exhibit 11: CPBI trades below its five-year average P/E of 46x


Source: Bloomberg, Company, Elara Securities Estimate

Exhibit 12: Valuation

(INR)	
EPS - FY27E	20.4
EPS - FY28E	26.4
Target multiple (x)	40.0
EPS - September 2027E	23.4
Target Price	935


Source: Elara Securities Estimate

Exhibit 13: Change in estimates

(INR mn)	Old Estimates			New Estimates			(%) change		
	FY26	FY27	FY28	FY26	FY27	FY28	FY26	FY27	FY28
Revenue	54,180	61,628	69,767	52,800	62,017	71,391	(2.5)	0.6	2.3
EBITDA	6,710	8,710	10,483	6,512	8,637	10,358	(3.0)	(0.8)	(1.2)
EBITDA (%)	12.4	14.1	15.0	12.3	13.9	14.5	(7)	(17)	(49)
PAT	3,138	4,747	6,140	2,812	4,540	5,876	(10.4)	(4.4)	(4.3)
EPS (INR)	14.1	21.3	27.6	12.6	20.4	26.4	(10.4)	(4.2)	(4.3)
Target price (INR)	980			935			(4)		

Source: Elara Securities Estimate

Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
06-Oct-2023	Buy	800	653
06-Feb-2024	Accumulate	850	734
27-May-2024	Accumulate	770	656
07-Aug-2024	Accumulate	805	707
30-Aug-2024	Buy	970	784
02-Jun-2025	Accumulate	880	784
08-Aug-2025	Buy	880	738
13-Nov-2025	Buy	980	764
20-Jan-2026	Buy	935	726

Guide to Research Rating

BUY (B)	Absolute Return >+20%
ACCUMULATE (A)	Absolute Return +5% to +20%
REDUCE (R)	Absolute Return -5% to +5%
SELL (S)	Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act")) may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/and> Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India
Elara Securities (India) Private Limited
 One International Center, Tower 3,
 21st Floor, Senapati Bapat Marg,
 Elphinstone Road (West)
 Mumbai – 400 013, India
 Tel : +91 22 6164 8500

Europe
Elara Capital Plc.
 6th Floor, The Grove,
 248A Marylebone Road,
 London, NW1 6JZ,
 United Kingdom
 Tel : +44 20 7486 9733

USA
Elara Securities Inc.
 230 Park Avenue, Suite 2415,
 New York, NY 10169, USA
 Tel: +1 212 430 5870
 Fax: +1 212 208 2501

Asia / Pacific
Elara Capital (Asia) Pte.Ltd.
 One Marina Boulevard,
 Level 20,
 Singapore 018989
 Tel : +65 6978 4047



**Managing
Director**

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



**Head of
Research**

Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572

Sales Team



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586



**India, APAC &
Australia**

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



**Corporate
Access,
Conference &
Events**

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#).

Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500
 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236
 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018
 Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509
 Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509